Withings ScanWatch has received CE certification for medical devices and is now available in Europe.
ScanWatch was developed by cardiologists and sleep experts and, according to Withings, is the world’s first clinically validated hybrid smartwatch to detect both atrial fibrillation (AFib) and night breathing disorders.
The smart watch is designed to help users and their doctors monitor their overall health status through early identification of cardiovascular, respiratory and night breathing problems.
ScanWatch can track a 30-second ECG and detect atrial fibrillation, measure heart rate and send heart rate notifications (high or low heart rate, irregular heartbeat).
Through photoplethysmography (PPG), it measures the oxygen saturation level (SpO2) and detects night breathing disturbances.
The smartwatch detects steps, distance, metabolic calories and total calorie consumption, swimming, deep and light sleep phases, as well as its interruptions. It records your fitness level by evaluating VO2Max, meters and scaled floors.
ScanWatch has a GPS and a truly remarkable autonomy: over 30 days! It synchronizes with the Health Mate app that provides many functions and information.
The cost to the public is 279.95 euros.